800 – Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib As an Induction Therapy in Adults with Moderately-To-Severely Active Ulcerative Colitis: Data from the U-Achieve Study
William J. Sandborn(University of San Diego), Edward V. Loftus(Mayo Clinic), James O. Lindsay(Barts Health NHS Trust), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Wen Zhou(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bidan Huang(AbbVie (United States)), Scott D. Lee(University of Washington), Ana P. Lacerda(AbbVie (United States)), Wangang Xie(AbbVie (United States)), Xavier Hébuterne, Fabio Cataldi(Pfizer (United States))
Cited by 4
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k